183170-90-3

Usage

Uses

Used in Organic Synthesis:
1-Benzyloxynapthalene-4-boronic acid serves as a reagent in organic synthesis, where it is utilized for the formation of carbon-carbon and carbon-heteroatom bonds. Its ability to form stable complexes with diols and amines makes it an indispensable tool in this field.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 1-benzyloxynaphthalene-4-boronic acid is applied for its versatile reactivity, which aids in the development of new pharmaceutical compounds. Its capacity to functionalize molecules contributes to the creation of potential drug candidates.
Used in Pharmaceutical Development:
1-Benzyloxynapthalene-4-boronic acid is employed in the development of pharmaceuticals due to its potential to enhance the properties of drug molecules. Its incorporation can lead to improved efficacy, selectivity, or other desirable characteristics in medicinal agents.
Used in Agrochemical Development:
Similarly, in agrochemical development, this boronic acid derivative is used to create new compounds with enhanced properties for agricultural applications, such as pest control or crop protection.
Each of these applications underscores the importance of 1-benzyloxynaphthalene-4-boronic acid as a versatile and valuable compound in the fields of organic synthesis, medicinal chemistry, pharmaceutical development, and agrochemical development.

Upstream product

• 138865-41-5 1-(benzyloxy)-4-bromonaphthalene 
• 5419-55-6 Triisopropyl borate 
• 7732-18-5 water 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 571-57-3 4-bromo-1-naphthol 
• 90-15-3 α-naphthol 

Downstream Products

• 221087-65-6 2-(2,5-dimethylpyrrolyl)-6-(4-benzyloxy-1-naphthyl)pyridine 
• 1010688-56-8 C₃₇H₃₇NO₃ 

Relevant academic research and scientific papers

RNAI AGENTS FOR INHIBITING EXPRESSION OF BETA-ENAC, COMPOSITIONS THEREOF, AND METHODS OF USE

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a beta-ENaC (SCNN1B) gene. The beta-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a beta-ENaC gene. Pharmaceutical comp

NOVEL PHENYL NAPTHOL DERIVATIVE

Phenylnaphthol derivatives represented by the following general formula (1), wherein, R 1 to R 3 are hydrogen atoms, alkyl groups or aryl groups, and R 2 and R 3 may be bonded together to form an aliphatic hydrocarbon ring or a heterocyclic ring, a and b are, respectively, integers of 0 to 4, R 4 and R 5 are hydroxyl groups, alkyl groups, haloalkyl groups, cycloalkyl groups, alkoxy groups, amino groups, heterocyclic groups having a nitrogen atom as a hetero atom and are bonded together via the nitrogen atom, cyano groups, nitro groups, formyl groups, hydroxycarbonyl groups, alkylcarbonyl groups, alkoxycarbonyl groups, halogen atoms, aralkylgroups, aralkoxy groups, aryloxy groups, aryl groups, heteroaryl groups bonded together via a carbon atom in the ring, alkylthio groups, cycloalkylthio groups, arylthio groups or heteroarylthio groups, and if R 4 or R 5 are present in a plural number, the plurality of R 4 or the plurality of R 5 may be the same or different, or 2 R 4 s or 2 R 5 s may be bonded together to form an alicyclic hydrocarbon ring or a heterocyclic ring. The compounds are useful as intermediate products for the synthesis of, for example, photochromic compounds.

NOVEL PHENYLNAPHTHOL DERIVATIVES

Phenylnaphthol derivatives represented by the following general formula (1), wherein, R1 to R3 are hydrogen atoms, alkyl groups or aryl groups, and R2 and R3 may be bonded together to form an aliphatic hydrocarbon ring or a heterocyclic ring, a and b are, respectively, integers of 0 to 4, R4 and R5 are hydroxyl groups, alkyl groups, haloalkyl groups, cycloalkyl groups, alkoxy groups, amino groups, heterocyclic groups having a nitrogen atom as a hetero atom and are bonded together via the nitrogen atom, cyano groups, nitro groups, formyl groups, hydroxycarbonyl groups, alkylcarbonyl groups, alkoxycarbonyl groups, halogen atoms, aralkyl groups, aralkoxy groups, aryloxy groups, aryl groups, heteroaryl groups bonded together via a carbon atom in the ring, alkylthio groups, cycloalkylthio groups, arylthio groups or heteroarylthio groups, and if R4 or R5 are present in a plural number, the plurality of R4 or the plurality of R5 may be the same or different, or 2 R4s or 2 R5s may be bonded together to form an alicyclic hydrocarbon ring or a heterocyclic ring. The compounds are useful as intermediate products for the synthesis of, for example, photochromic compounds.

Structure-Activity Relationships of Potent, Selective Inhibitors of Neuronal Nitric Oxide Synthase Based on the 6-Phenyl-2-aminopyridine Structure

The synthesis and structure-activity relationships of a series of 6-phenyl-2-aminopyridines that potently and selectively inhibit the neuronal isoform of nitric oxide synthase (nNOS) are described. Compound 14bi from this series exhibits potent in vivo activity in harmaline-induced cGMP formation in rat cerebellum, a functional model of nNOS inhibition, and in the PCP-induced hypermotility model in the rat. These results suggest that 14bi may be a useful reagent for evaluating potential therapeutic applications of nNOS inhibitors in the central nervous system.

2-aminopyridines containing fused ring substituents

The present invention relates to 2-aminopyridine derivatives of the formula wherein G, R1 and R2 are defined as in the specification, that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.